Phenols in pharmaceuticals: analysis of a recurring motif

KA Scott, PB Cox, JT Njardarson - Journal of Medicinal Chemistry, 2022 - ACS Publications
Phenols and phenolic ethers are significant scaffolds recurring both in nature and among
approved small-molecule pharmaceuticals. This compendium presents the first …

[HTML][HTML] Podophyllotoxin: a novel potential natural anticancer agent

H Ardalani, A Avan… - Avicenna journal of …, 2017 - ncbi.nlm.nih.gov
Objective: The aim of the present review is to give an overview about the role, biosynthesis,
and characteristics of Podophyllotoxin (PTOX) as a potential antitumor agent with particular …

2019 IUSTI‐Europe guideline for the management of anogenital warts

R Gilson, D Nugent, RN Werner… - Journal of the …, 2020 - Wiley Online Library
This guideline is an update of the 2011 European Guideline for the Management of
Anogenital Warts. It is intended to support best practice in the care of patients with …

External genital warts: diagnosis, treatment, and prevention

DJ Wiley, J Douglas, K Beutner, T Cox… - Clinical Infectious …, 2002 - academic.oup.com
External genital warts (EGWs) are visible warts that occur in the perigenital and perianal
regions. They are due primarily to non-oncogenic human papillomavirus (HPV) types …

2012 European guideline for the management of anogenital warts

CJN Lacey, SC Woodhall, A Wikstrom… - Journal of the …, 2013 - Wiley Online Library
Background Although new HPV vaccines have been developed and are in the process of
implementation, anogenital warts remain a very frequent problem in clinical practice …

[HTML][HTML] Current and future direction in treatment of HPV-related cervical disease

N Khairkhah, A Bolhassani, R Najafipour - Journal of Molecular Medicine, 2022 - Springer
Human papillomavirus (HPV) is the most common sexually transmitted virus in the world.
About 70% of cervical cancers are caused by the most oncogenic HPV genotypes of 16 and …

Treatment of genital warts with an immune-response modifier (imiquimod)

KR Beutner, SL Spruance, AJ Hougham, TL Fox… - Journal of the American …, 1998 - Elsevier
Background: Genital warts are a common sexually transmitted disease caused by human
papillomavirus. Imiquimod is a novel immune-response modifier capable of inducing a …

Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts

KR Beutner, SK Tyring, KF Trofatter Jr… - Antimicrobial agents …, 1998 - Am Soc Microbiol
Genital human papillomavirus infection is one of the most common sexually transmitted
diseases. Imiquimod is a new agent, an immune-response modifier, that has been …

[HTML][HTML] Biocatalytic routes to anti-viral agents and their synthetic intermediates

S Slagman, WD Fessner - Chemical Society Reviews, 2021 - pubs.rsc.org
With recent outbreaks of COVID-19 and Ebola, health and healthcare have once more
shown to be heavily burdened by the lack of generally effective anti-viral therapies. Initial …

Position statement for the diagnosis and management of anogenital warts

C O'Mahony, M Gomberg, M Skerlev… - Journal of the …, 2019 - Wiley Online Library
Background Anogenital warts (AGW) can cause economic burden on healthcare systems
and are associated with emotional, psychological and physical issues. Objective To provide …